The IMIDomics Precision Discovery Engine™ integrates and analyzes clinical, epidemiologic and biomolecular data, to target and discover new therapeutic possibilities.
A curated, secure library of IMID patient data provides answers that will lead to more accurate diagnosis and therapies.
IMIDomics’ access to the Vall d’Hebron Hospital IMID Biobank offers a unique window into patient experiences, medical conditions and underlying disease mechanisms – the crucial data required to enable meaningful discovery.
IMIDomics applies the latest multi-omics approaches, including genomics, proteomics and single cell analysis, to generate sophisticated data. This data is then integrated with the clinical data to derive deep insights about IMID patients and conditions.
Inspired by Patients
IMIDs - including conditions like systemic lupus, rheumatoid arthritis, Crohn’s disease and psoriasis - afflict millions of people, creating health challenges that too often limit patients’ opportunities and significantly reduce their quality of life. In most cases, these diseases are chronic, incurable and continue to evolve over time, presenting new challenges to patients.
Each year, billions of dollars are spent treating patients with these conditions. However, current treatments are limited, resulting in some patients experiencing side effects with existing treatments while others are unable to find any relief at all. In fact, there are no curative medicines for these patients. The demand for new, effective therapies is therefore very significant – and these medicines can only come from a better understanding of these uniquely challenging diseases.
IMIDomics’ work is powered by our Precision Discovery Engine. This advanced and highly-focused analytics solution is built upon 15 years of innovation, forging connections with IMID patients and their physicians, and collecting a wealth of data and samples. This foundational work enables IMIDomics to lead in the discovery and development of new IMID treatments.
IMID Clinical Consortium led by VHIR
Cross-sectional IMID Grant Awarded
Establishment of the IMID-Biobank
ISO 9001 Certification
First Cohort Collected
HudsonAlpha Institute for Biotechnology Partnership
Longitudinal IMID cohort grant awarded
Continued Cohort Collection and Analysis
Becton, Dickinson and Company Collaboration
H2020 EU Framework Grant
Gossamer and BMS collaborations
Series A Financing
Strategic investment from EVOTEC SE
Bioèxit Award from CataloniaBio & HealthTech